icon-folder.gif   Conference Reports for NATAP  
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
June 22-26 2022
Back grey_arrow_rt.gif
Combination treatment of a PAPD5/7 inhibitor with an antisense oligonucleotide bepirovirsen with concurrent dosing shows additive HBsAg decreases in the AAV-HBV mouse model
  EASL 2022 June 22-26 London
Jared Delahaye, Edward Long, Chi Lau, Jacob Parsons, Bo Wen, Zhiyi Cui, Melanie Paff, Shihyun You, Martin Leivers
GlaxoSmithKline Research and Development, Upper Providence, PA, USA


EASL: Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection: interim results from the randomised Phase 2b B-Clear study - (06/26/22)
from Ed Gane's talk at EASL 2022







Hangfei Qi, Douglas Thomson, H. Christian Eberl, Stephanie Lehmann, Mi Xie, Jeff Carson, Patti McCormick, Yingnian Shen, Warren Rocque, Pek Chong, Hamilton Dickson, Thilo Werner, Marcus Bantscheff JD, EL, CL, JP, BW, ZC, MP, SY and ML are GSK employees and my hold stock/shares in GSK. All studies were conducted in accordance with the GSK Policy on the Care, Welfare and Treatment of Laboratory Animals and were reviewed the Institutional Animal Care and Use Committee either at GSK or by the ethical review process at the institution where the work was performed.